JMKX001149

JMKX001149 is a small molecule drug candidate developed by Jiangxi Jemincare Group. It is being investigated primarily for the treatment of cardiovascular and nervous system diseases, with active indications including brain infarction and myocardial infarction. The compound has also been explored for venous thromboembolism but is not currently active in that indication. As of the latest updates, its highest development status globally is preclinical, though at least two phase 1 clinical trials were initiated to evaluate its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy subjects; these trials have since been suspended or terminated. The precise mechanism of action and molecular targets have not been publicly disclosed[1][7].